RÉSUMÉ
PURPOSE: To review long-term outcomes of circumscribed choroidal hemangioma (CCH). METHODS: Hospital charts of all CCH cases diagnosed from 2008 to 2019 were retrospectively reviewed. RESULTS: All 172 patients were managed with either observation, transpupillary thermotherapy, argon laser photocoagulation, photodynamic therapy, plaque brachytherapy or stereotactic radiosurgery. The most common 3 modes of management were clinical observation (30.2%), transpupillary thermotherapy (52.9%) and argon laser photocoagulation (8.7%). Median follow-up time was 10 months (range: 3, 160). Anatomical outcomes were stable in 87.1% of observation group and improved in 60.5% of thermotherapy group. Quantified optical coherence tomography angiography findings showed statistical differences in vascular and perfusion densities in fellow eyes of hemangioma patients. CONCLUSION: Circumscribed choroidal hemangioma can be treated in various ways. Transpupillary thermotherapy is an anatomically effective treatment in selected cases. The diagnosis of CCH may have vascular implications in fellow eyes of the patients.
Sujet(s)
Tumeurs de la choroïde , Angiographie fluorescéinique , Hémangiome , Centres de soins tertiaires , Tomographie par cohérence optique , Acuité visuelle , Humains , Tumeurs de la choroïde/thérapie , Tumeurs de la choroïde/diagnostic , Femelle , Mâle , Études rétrospectives , Adulte d'âge moyen , Tomographie par cohérence optique/méthodes , Angiographie fluorescéinique/méthodes , Adulte , Centres de soins tertiaires/statistiques et données numériques , Hémangiome/thérapie , Hémangiome/diagnostic , Sujet âgé , Études de suivi , Photothérapie dynamique/méthodes , Hyperthermie provoquée/méthodes , Fond de l'oeil , Jeune adulte , Choroïde/anatomopathologie , Choroïde/vascularisationRÉSUMÉ
Infantile hemangioma is a benign vascular tumor, the most common in childhood, whose natural evolution is the disappearance of the lesion in the pediatric age and which has effective and safe treatments that limit its growth and favor its disappearance at younger ages. Infantile hemangioma continues to be a reason for attention to complications, due to erroneous diagnoses, lack of knowledge of the condition, late referral or fear of the effects of the medications used for its treatment. Furthermore, its presence is normalized without taking into account that it can cause uncertainty, anxiety, feelings of guilt and, as a consequence, a significant impact on the quality of life, mainly in the parents or caregivers of the child. The need for a clinical practice guideline in our country arises from the high presentation of late-remitted complications in infantile hemangioma even with the availability of adequate treatments, the continuous evolution of medicine and the appearance of new evidence. Throughout the guide you will find recommendations regarding the diagnosis, treatment and follow-up of patients with infantile hemangioma, taking into account the paraclinical tests that can be performed, topical or systemic management options, as well as adjuvant therapies. For the first time, objective tools for patient follow-up are included in a guide for the management of infantile hemangioma, as well as to help the first contact doctor in timely referral.
El hemangioma infantil es un tumor vascular benigno, el más frecuente de la infancia, cuya evolución natural favorece la desaparición de la lesión en la misma edad pediátrica y que cuenta con tratamientos eficaces y seguros que limitan su crecimiento y favorecen su desaparición a edades más tempranas. Continúa siendo motivo de atención de complicaciones, debido a diagnósticos erróneos, desconocimiento del padecimiento, referencia tardía o temor de los efectos de los fármacos utilizados para su tratamiento. Además, se normaliza su presencia sin tomar en cuenta que puede llegar a causar incertidumbre, ansiedad, sentimientos de culpa y, como consecuencia, importante afectación de la calidad de vida, principalmente en los padres o cuidadores del niño. La necesidad de una guía de práctica clínica en nuestro país surge ante la alta presentación de complicaciones del hemangioma infantil referidas de manera tardía aun con la disponibilidad de tratamientos adecuados, la evolución continua de la medicina y la aparición de nueva evidencia. A lo largo de la guía se encontrarán recomendaciones en relación con el diagnóstico, el tratamiento y el seguimiento de los pacientes con hemangioma infantil, tomando en cuenta los paraclínicos que pueden realizarse, las opciones de manejo tópico o sistémico, y las terapias adyuvantes. Por primera vez se incluyen en una guía para el manejo del hemangioma infantil herramientas objetivas para el seguimiento de los pacientes, así como para ayudar al médico de primer contacto en su referencia oportuna.
Sujet(s)
Hémangiome , Humains , Nourrisson , Études de suivi , Hémangiome/diagnostic , Hémangiome/thérapie , Mexique , Qualité de vieRÉSUMÉ
Focal liver lesions (FLLs) have become an increasingly common finding on abdominal imaging, especially asymptomatic and incidental liver lesions. Gastroenterologists and hepatologists often see these patients in consultation and make recommendations for management of multiple types of liver lesions, including hepatocellular adenoma, focal nodular hyperplasia, hemangioma, and hepatic cystic lesions including polycystic liver disease. Malignancy is important to consider in the differential diagnosis of FLLs, and healthcare providers must be familiar with the diagnosis and management of FLLs. This American College of Gastroenterology practice guideline uses the best evidence available to make diagnosis and management recommendations for the most common FLLs.
Sujet(s)
Adénome hépatocellulaire , Kystes , Hyperplasie focale nodulaire , Hémangiome , Maladies du foie , Tumeurs du foie , Humains , Hyperplasie focale nodulaire/diagnostic , Hyperplasie focale nodulaire/anatomopathologie , Tumeurs du foie/diagnostic , Tumeurs du foie/anatomopathologie , Tumeurs du foie/thérapie , Tumeurs du foie/imagerie diagnostique , Maladies du foie/diagnostic , Maladies du foie/thérapie , Maladies du foie/imagerie diagnostique , Maladies du foie/anatomopathologie , Hémangiome/diagnostic , Hémangiome/thérapie , Hémangiome/anatomopathologie , Hémangiome/imagerie diagnostique , Kystes/diagnostic , Kystes/imagerie diagnostique , Kystes/anatomopathologie , Adénome hépatocellulaire/diagnostic , Adénome hépatocellulaire/anatomopathologie , Adénome hépatocellulaire/thérapie , Adénome hépatocellulaire/imagerie diagnostique , Diagnostic différentiel , Gastroentérologie/normes , Carcinome hépatocellulaire/diagnostic , Carcinome hépatocellulaire/anatomopathologie , Carcinome hépatocellulaire/thérapie , Carcinome hépatocellulaire/imagerie diagnostiqueRÉSUMÉ
PURPOSE: To investigate the swept-source optical coherence tomography (SS-OCT) and SS-OCT angiography (SS-OCTA) findings in circumscribed choroidal hemangioma (CCH) before and after treatment with transpupillary thermotherapy (TTT). METHODS: The clinical records of 21 eyes having CCH imaged with SS-OCT/SS-OCTA between September 2018 and December 2022 were evaluated. RESULTS: SS-OCT examination in CCH showed dome-shaped appearance (100%), choroidal shadowing (100%), expansion of choroidal structures (100%), subretinal fluid (66.7%), intraretinal edema/schisis (33.3%), retinal pigment epithelium (RPE) atrophy (19.0%), hyperreflective dots (19.0%), and epiretinal membrane (4.8%). Internal arborizing tumor vessels showing hyperreflectivity were observed in the choriocapillaris slab on SS-OCTA in all eyes. In the deep capillary plexus (DCP), flow void changes were seen in 7 eyes with intraretinal schisis/cystoid macular edema. Four CCHs > 2 mm in thickness showed outer retinal involvement due to unmasking of flow in intratumoral vessels related to RPE atrophy. Following TTT/indocyanine green-enhanced TTT (ICG-TTT) of CCH, SS-OCT findings included total/partial resolution of subretinal fluid (57.1%), complete/partial regression of the tumor (52.4%), and RPE atrophy (33.3%). After treatment; loss of choriocapillaris, decrease in tumor vascularity together with increase in the fibrous component and flow void areas were detected on SS-OCTA. CONCLUSIONS: SS-OCT/SS-OCTA are useful non-invasive tools for imaging the structural/vascular changes in CCHs managed with TTT or ICG-TTT. On SS-OCTA, hyporeflective spaces localizing to edema/schisis in the DCP and arborizing tumor vessels within a hyporeflective stromal background in the choriocapillaris slab were observed. After TTT/ICG-TTT, a decrease in tumor vessels and an increase in the fibrous component and flow-void areas inside the CCH were detected on SS-OCTA.
Sujet(s)
Tumeurs de la choroïde , Hémangiome , Hyperthermie provoquée , Tomographie par cohérence optique , Humains , Tomographie par cohérence optique/méthodes , Tumeurs de la choroïde/thérapie , Tumeurs de la choroïde/imagerie diagnostique , Tumeurs de la choroïde/anatomopathologie , Femelle , Adulte d'âge moyen , Mâle , Hémangiome/thérapie , Hémangiome/imagerie diagnostique , Hémangiome/anatomopathologie , Adulte , Hyperthermie provoquée/méthodes , Sujet âgé , Angiographie fluorescéinique/méthodes , Études rétrospectives , Choroïde/imagerie diagnostique , Choroïde/vascularisation , Choroïde/anatomopathologieRÉSUMÉ
BACKGROUND: Vertebral hemangiomas (VHs) are the most common benign tumors of the spinal column and are often encountered incidentally during routine spinal imaging. METHODS: A retrospective review of the inpatient and outpatient hospital records at our institution was performed for the diagnosis of VHs from January 2005 to September 2023. Search filters included "vertebral hemangioma," "back pain," "weakness," "radiculopathy," and "focal neurological deficits." Radiographic evaluation of these patients included plain X-rays, CT, and MRI. Following confirmation of a diagnosis of VH, these images were used to generate the figures used in this manuscript. Moreover, an extensive literature search was conducted using PubMed for the literature review portion of the manuscript. RESULT: VHs are benign vascular proliferations that cause remodeling of bony trabeculae in the vertebral body of the spinal column. Horizontal trabeculae deteriorate leading to thickening of vertical trabeculae which causes a striated appearance on sagittal magnetic resonance imaging (MRI) and computed tomography (CT), "Corduroy sign," and a punctuated appearance on axial imaging, "Polka dot sign." These findings are seen in "typical vertebral hemangiomas" due to a low vascular-to-fat ratio of the lesion. Contrarily, atypical vertebral hemangiomas may or may not demonstrate the "Corduroy" or "Polka-dot" signs due to lower amounts of fat and a higher vascular component. Atypical vertebral hemangiomas often mimic other neoplastic pathologies, making diagnosis challenging. Although most VHs are asymptomatic, aggressive vertebral hemangiomas can present with neurologic sequelae such as myelopathy and radiculopathy due to nerve root and/or spinal cord compression. Asymptomatic vertebral hemangiomas do not require therapy, and there are many treatment options for vertebral hemangiomas causing pain, radiculopathy, and/or myelopathy. Surgery (corpectomy, laminectomy), percutaneous techniques (vertebroplasty, sclerotherapy, embolization), and radiotherapy can be used in combination or isolation as appropriate. Specific treatment options depend on the lesion's size/location and the extent of neural element compression. There is no consensus on the optimal treatment plan for symptomatic vertebral hemangioma patients, although management algorithms have been proposed. CONCLUSION: While typical vertebral hemangioma diagnosis is relatively straightforward, the differential diagnosis is broad for atypical and aggressive lesions. There is an ongoing debate as to the best approach for managing symptomatic cases, however, surgical resection is often considered first line treatment for patients with neurologic deficit.
Sujet(s)
Hémangiome , Imagerie par résonance magnétique , Tumeurs du rachis , Humains , Hémangiome/thérapie , Hémangiome/imagerie diagnostique , Hémangiome/diagnostic , Tumeurs du rachis/thérapie , Tumeurs du rachis/imagerie diagnostique , Études rétrospectives , Tomodensitométrie , Mâle , Femelle , Adulte d'âge moyenRÉSUMÉ
Vascular anomalies in the head and neck area are usually rare diseases and pose a particular diagnostic and therapeutic challenge. They are divided into vascular tumours and vascular malformations. A distinction is made between benign tumours, such as infantile haemangioma, and rare malignant tumours, such as angiosarcoma. Vascular malformations are categorised as simple malformations, mixed malformations, large vessel anomalies and those associated with other anomalies. Treatment is interdisciplinary and various modalities are available. These include clinical observation, sclerotherapy, embolisation, ablative and coagulating procedures, surgical resection and systemic drug therapy. Treatment is challenging, as vascular anomalies in the head and neck region practically always affect function and aesthetics. A better understanding of the genetic and molecular biological basis of vascular anomalies has recently led to clinical research into targeted drug therapies. This article provides an up-to-date overview of the diagnosis, clinic and treatment of vascular anomalies in the head and neck region.
Sujet(s)
Cou , Anomalies vasculaires , Humains , Association thérapeutique , Embolisation thérapeutique , Tête/vascularisation , Tumeurs de la tête et du cou/thérapie , Tumeurs de la tête et du cou/diagnostic , Hémangiome/thérapie , Hémangiome/diagnostic , Communication interdisciplinaire , Collaboration intersectorielle , Cou/vascularisation , Équipe soignante , Sclérothérapie , Anomalies vasculaires/thérapie , Anomalies vasculaires/diagnosticRÉSUMÉ
Vascular anomalies represent a diverse group of disorders of abnormal vascular development or proliferation. Vascular anomalies are classified as vascular tumors and vascular malformations. Significant advances have been made in the understanding of the pathogenesis, natural history, and genetics of vascular anomalies, allowing for improvements in management including targeted molecular therapies. Infantile hemangiomas are the most common vascular tumor of childhood and follow a distinct natural history of proliferation and involution. Although benign, infantile hemangiomas can be associated with important complications. The use of beta-blockers has revolutionized the management of infantile hemangiomas. Other vascular tumors include pyogenic granulomas, congenital hemangiomas, and kaposiform hemangioendotheliomas, among others. Vascular malformations are categorized based on the type of involved vessel, including capillary malformations, venous malformations, lymphatic malformations, arteriovenous malformations, and mixed vascular malformations. Expert multidisciplinary management of vascular anomalies is critical to optimize outcomes in these patients. [Pediatr Ann. 2024;53(4):e129-e137.].
Sujet(s)
Hémangioendothéliome , Hémangiome , Syndrome de Kasabach-Merritt , Anomalies vasculaires , Tumeurs vasculaires , Humains , Tumeurs vasculaires/diagnostic , Tumeurs vasculaires/thérapie , Anomalies vasculaires/diagnostic , Anomalies vasculaires/thérapie , Anomalies vasculaires/anatomopathologie , Hémangiome/diagnostic , Hémangiome/thérapie , Hémangiome/anatomopathologieRÉSUMÉ
An outborn male term neonate presented with a complaint of respiratory distress since birth on day 9 of life. On examination, baby was having tachypnoea, tachycardia and hepatomegaly. The baby was delivered at term gestation and cried immediately after birth. The chest X-ray showed cardiomegaly. The abdomen ultrasound showed a complex cystic vascular lesion suggestive of hepatic haemangioma. The echocardiography showed an atrial septal defect. The baby was initially treated conservatively along with specific treatment (steroids and propranolol) for haemangioma for 6 weeks. However, the symptoms persisted and there was non-resolution, therefore, particle embolisation of the right hepatic artery was performed. Subsequently, it resulted in complete resolution of the lesion.
Sujet(s)
Hémangiome , Tumeurs du foie , Nouveau-né , Nourrisson , Humains , Mâle , Hémangiome/imagerie diagnostique , Hémangiome/thérapie , Tumeurs du foie/imagerie diagnostique , Tumeurs du foie/thérapie , Propranolol/usage thérapeutique , Artère hépatique , ÉchographieRÉSUMÉ
Hepatic hemangiomas are the most common benign liver tumors. Typically, small- to medium-sized hemangiomas are asymptomatic and discovered incidentally through the widespread use of imaging techniques. Giant hemangiomas (>5 cm) have a higher risk of complications. A variety of imaging methods are used for diagnosis. Cavernous hemangioma is the most frequent type, but radiologists must be aware of other varieties. Conservative management is often adequate, but some cases necessitate targeted interventions. Although surgery was traditionally the main treatment, the evolution of minimally invasive procedures now often recommends transarterial chemoembolization as the treatment of choice.
Sujet(s)
Carcinome hépatocellulaire , Chimioembolisation thérapeutique , Hémangiome caverneux , Hémangiome , Tumeurs du foie , Humains , Tumeurs du foie/imagerie diagnostique , Tumeurs du foie/thérapie , Tumeurs du foie/anatomopathologie , Carcinome hépatocellulaire/thérapie , Imagerie par résonance magnétique/méthodes , Hémangiome/imagerie diagnostique , Hémangiome/thérapie , Hémangiome caverneux/imagerie diagnostique , Hémangiome caverneux/thérapieRÉSUMÉ
OBJECTIVE: The objective of this study was to evaluate the safety and effectiveness of radiofrequency ablation (RFA) and transcatheter arterial chemoembolization (TACE) in the treatment of large hepatic hemangiomas (LHH) (5-9.9 cm in diameter). METHODS AND MATERIALS: This study retrospectively collected data from 82 patients with LHH treated at Chaoyang Central Hospital. The study analyzed the differences in postoperative efficacy, operative time, blood routine, liver and kidney function on the first day after surgery, postoperative hospitalization time and postoperative complications. RESULTS: There were statistically significant differences in indicators such as white blood cell count, alanine aminotransferase, aspartate aminotransferase and total bilirubin on the first day after surgery between the RFA group (39 cases) and the TACE group (43 cases) ( P < 0.001). Compared to RFA, LHH patients treated with TACE had a general complication rate of 39.5% (vs. 43.6%; P = 0.7), a procedure-related complication rate of 30.2% (vs. 59.0%; P = 0.009), an effective rate at 6-12 months postoperatively of 55.8% (vs. 82.1%; P = 0.01), an operating-time of 41.2 ± 14.9 min (vs. 100.8 ± 35.5 min; P < 0.001) and hospitalization costs of 17052.7 ± 1364.8 yuan (vs. 30952.1 ± 4327.6 yuan; P < 0.001). CONCLUSION: This study indicates that the efficacy of RFA in treating LHH is significantly superior to TACE. Microwave ablation and RFA appear to be safe treatments for LHH. The TACE group exhibited shorter operating-time, lower hospitalization costs and lower demands on cardiopulmonary function.
Sujet(s)
Chimioembolisation thérapeutique , Hémangiome , Tumeurs du foie , Durée opératoire , Humains , Mâle , Femelle , Tumeurs du foie/thérapie , Adulte d'âge moyen , Études rétrospectives , Résultat thérapeutique , Hémangiome/thérapie , Adulte , Chimioembolisation thérapeutique/méthodes , Chimioembolisation thérapeutique/effets indésirables , Ablation par radiofréquence/effets indésirables , Ablation par radiofréquence/méthodes , Durée du séjour , Sujet âgé , Complications postopératoires/étiologie , Ablation par cathéter/méthodes , Ablation par cathéter/effets indésirables , Facteurs temps , Charge tumoraleRÉSUMÉ
PURPOSE: To evaluate the safety, efficacy and predictors of response of transcatheter arterial embolization (TAE) to treat hepatic hemangiomas (HHs). MATERIALS AND METHODS: A retrospective analysis was conducted of consecutive HH patients who received TAE with bleomycin-Lipiodol emulsion and gelatin sponge particles at three institutions from January 2014 to January 2021. TAE effectiveness was defined as more than 50% reduction of tumor volume. The effectiveness, safety, and CT changes of hemangiomas after TAE were assessed. Factors affecting TAE efficacy on tumor size were analyzed with logistic regression analysis. RESULTS: A total of 102 patients with 109 HHs were included. After treatment, both the tumor diameter and volume were significantly reduced from 8.5 ± 3.9 to 5.9 ± 3.8 cm (P < 0.001) and 412.6 ± 742.3 cm3 to 102.0 ± 232.7 cm3 (P < 0.001), respectively. TAE effectiveness was achieved in 80.7% (88/109) of hemangiomas, which was characterized by progressive reduction in tumor volume over time with Lipiodol retention. Atypical enhancement pattern (tiny enhancing dots in the hepatic arterial and portal venous phase) (p = 0.001) and central arterioportal shunt (APS) (p = 0.002) associated with the tumor were independent predictors of TAE ineffectiveness. Postembolization syndrome and transient increase in liver enzymes were common without severe complications and death. CONCLUSION: TAE was safe and effective in reducing HH size. Lesion enhancement pattern and APS type were associated with TAE efficacy on tumor shrinkage. LEVEL OF EVIDENCE: Level 3, non-controlled retrospective cohort study.
Sujet(s)
Bléomycine , Huile éthiodée , Hémangiome , Tumeurs du foie , Humains , Mâle , Études rétrospectives , Femelle , Huile éthiodée/administration et posologie , Huile éthiodée/usage thérapeutique , Tumeurs du foie/thérapie , Tumeurs du foie/imagerie diagnostique , Adulte d'âge moyen , Bléomycine/usage thérapeutique , Hémangiome/thérapie , Hémangiome/imagerie diagnostique , Adulte , Résultat thérapeutique , Sujet âgé , Embolisation thérapeutique/méthodes , Antibiotiques antinéoplasiques/usage thérapeutique , Antibiotiques antinéoplasiques/administration et posologie , Charge tumorale , Chimioembolisation thérapeutique/méthodes , Éponge de gélatine résorbable/usage thérapeutiqueRÉSUMÉ
Hemangiomas are most common benign liver tumor. Most patients have an excellent prognosis because of the small size and benign nature of tumor. On some occasions, giant liver hemangioma may cause symptoms and significant challenges due to its complication. We report a case of giant liver hemangioma treated with minimal invasive approach by transarterial embolization (TAE). Following three TAE sessions over a specific timeframe, the patient was successfully managed, addressing that TAE may be a useful alternative to hepatic surgery in such cases.
Sujet(s)
Bléomycine , Embolisation thérapeutique , Huile éthiodée , Hémangiome , Tumeurs du foie , Humains , Tumeurs du foie/thérapie , Tumeurs du foie/imagerie diagnostique , Hémangiome/thérapie , Hémangiome/imagerie diagnostique , Huile éthiodée/administration et posologie , Bléomycine/administration et posologie , Bléomycine/usage thérapeutique , Embolisation thérapeutique/méthodes , Antibiotiques antinéoplasiques/administration et posologie , Antibiotiques antinéoplasiques/usage thérapeutique , Femelle , Mâle , Adulte d'âge moyen , Émulsions , Chimioembolisation thérapeutique/méthodesRÉSUMÉ
Growth in the research, innovation, and development of laser and energy-based technologies over the past few decades has led to dramatic increases in treatment options for dermatologic and cosmetic concerns of the periorbital area. We highlight recent treatment options using laser and energy-based devices for the clearance of periocular pigmented lesions, including solar lentigines and nevus of Ota; vascular lesions, including port-wine birthmarks, infantile hemangiomas, superficial telangiectasias, and reticular veins; laser ablation of benign tumors, such as xanthelasma; cosmetic rejuvenation; treatment of infraorbital dark circles and festoons; laser removal of eyebrow and eyeliner tattoos; and device-based treatment of chronic dry eyes.
Sujet(s)
Thérapie laser , Humains , Rajeunissement , Tatouage , Techniques cosmétiques/instrumentation , Tumeurs cutanées/thérapie , Tumeurs cutanées/chirurgie , Lentigo/thérapie , Télangiectasie/thérapie , Hémangiome/thérapieRÉSUMÉ
BACKGROUND: Hemangioma of the urinary bladder is a rare benign tumor. Although benign, their presenting symptoms are alarming for both patients and doctors, and their rarity makes them challenging to correctly diagnosis and treat. This review paper summarizes current knowledge about hemangioma of the urinary bladder, treatment options, and follow-up modalities. SUMMARY: After the kidney, the bladder is the second most common location of hemangiomas in the urinary tract. There is painless gross hematuria on clinical presentation once the lesion has eroded the urothelium. Magnetic resonance imaging (MRI) has been reported to be valuable in diagnosing soft-tissue hemangiomas. Cystoscopic findings of a sessile, blue, multilocular mass suggest hemangioma. Most tumors are solitary, smaller than 3 cm, and have smooth or irregular surfaces. Histologically, lesions comprise numerous proliferative capillaries with thin-walled, dilated, blood-filled vessels lined with flattened endothelium. The treatment of patients with hemangioma has been controversial. It depends on the tumor size and the degree of penetration. The prognosis of these tumors is excellent. KEY MESSAGES: Despite the widespread use of MRI, CT, and endoscopy in evaluating hematuria, hemangioma remains one of the rarest bladder tumors. Moreover, only a histological examination can confirm the diagnosis. Transurethral resection, fulguration, and YAG laser ablation are standard treatments for small tumors. In terms of follow-up, cystoscopy after 6 months of treatment helps assess recurrence. In addition, MRI is a practical, noninvasive technique for follow-up of small hemangiomas.
Sujet(s)
Hémangiome , Tumeurs de la vessie urinaire , Humains , Vessie urinaire/anatomopathologie , Hématurie/étiologie , Hématurie/anatomopathologie , Hémangiome/diagnostic , Hémangiome/thérapie , Hémangiome/anatomopathologie , Tumeurs de la vessie urinaire/diagnostic , Tumeurs de la vessie urinaire/thérapie , Tumeurs de la vessie urinaire/anatomopathologie , CystoscopieRÉSUMÉ
OBJECTIVES: To explore the clinical characteristics, postnatal treatment and prognosis of giant fetal hepatic hemangioma (GFHH). METHOD: Retrospective analysis was performed on children with giant fetal hepatic hemangioma (maximum tumor diameter > 40 mm) diagnosed by prenatal ultrasound and MRI from December 2016 to December 2020. These patients were observed and treated at the Children's Hospital of Fudan University after birth. The clinical data were collected to analyze the clinical characteristics, treatment, and prognosis of GFHH using independent sample t tests or Fisher's exact tests. RESULTS: Twenty-nine patients who were detected by routine ultrasound in the second and third trimester of pregnancy with giant fetal hepatic hemangiomas were included. The first prenatal ultrasound diagnosis of gestational age was 34.0 ± 4.3 weeks, ranging from 22 to 39 weeks. Of the patients, 28 had focal GFHHs and 1 had multifocal GFHHs. Surgery was performed, and the diagnosis was confirmed histopathologically in two patients. There were 8 cases with echocardiography-based evidence of pulmonary hypertension, 11 cases had a cardiothoracic ratio > 0.6, and 4 cases had hepatic arteriovenous fistula (AVF). The median follow-up time was 37 months (range: 14-70 months). During the follow-up, 12 patients received medical treatment with propranolol as the first-line therapy. The treatment group had a higher ratio of cardiothoracic ratio > 0.6 (P = 0.022) and lower albumin levels (P = 0.018). Four (14.8%) lesions showed postnatal growth before involuting. Complete response was observed in 13 (13/29) patients, and partial response was observed in 16 (16/29) patients. CONCLUSIONS: Fetal giant hepatic hemangioma is mainly localized, and its clinical outcome conforms to RICH (rapidly involuting) and PICH (partially involuting), but some fetal giant hepatic hemangiomas will continue to grow after birth and then gradually decrease. For uncomplicated giant fetal hepatic hemangioma, postnatal follow-up is the main concern, while those with complications require aggressive medical treatment. Propranolol may have no effect on the volume change of GFHH.
Sujet(s)
Hémangiome , Maladies néonatales , Tumeurs du foie , Grossesse , Nouveau-né , Enfant , Femelle , Humains , Nourrisson , Propranolol/usage thérapeutique , Études rétrospectives , Hémangiome/imagerie diagnostique , Hémangiome/thérapie , Tumeurs du foie/imagerie diagnostique , Tumeurs du foie/thérapie , Tumeurs du foie/anatomopathologieRÉSUMÉ
OBJECTIVE: The study aimed to compare the effectiveness and safety of ultrasound-guided microwave ablation (MWA) and percutaneous sclerotherapy (PS) for the treatment of large hepatic hemangioma (LHH). METHODS: This retrospective study included 96 patients who underwent MWA (n = 54) and PS (n = 42) as first-line treatment for LHH in three tertiary hospitals from January 2016 to December 2021. Primary outcomes were technique efficacy rate (volume reduction rate [VRR] > 50% at 12 months), symptom relief rate at 12 months and local tumor progression (LTP). Secondary outcomes included procedure time, major complications, treatment sessions, cost and one-, two-, three-year VRR. RESULTS: During a median follow-up of 36 months, the MWA group showed a higher technique efficacy rate (100% vs. 90.4%, p = .018) and symptom relief rate (100% vs. 80%, p = .123) than the PS group. The MWA group had fewer treatment sessions, higher one-, two- and three-year VRR, lower LTP rate (all p < .05), longer procedure time and higher treatment costs than the PS group (both p < .001). MWA shared a comparable major complications rate (1.8% vs. 2.4%, p = .432) with PS. After multivariate analysis, the lesion's heterogeneity and maximum diameter >8.1 cm were independent risk factors for LTP (all p < .05). In the PS group, lesions with a cumulative dose of bleomycin > 0.115 mg/cm3 had a lower risk of LTP (p = .006). CONCLUSIONS: Both MWA and PS treatments for large hepatic hemangioma are safe and effective, with MWA being superior in terms of efficacy.
Sujet(s)
Hémangiome , Tumeurs du foie , Humains , Sclérothérapie , Micro-ondes/usage thérapeutique , Études rétrospectives , Hémangiome/imagerie diagnostique , Hémangiome/thérapie , Tumeurs du foie/thérapieRÉSUMÉ
Benign tumors of the eye and eyelid are common in children and adults, and they rarely undergo malignant transformation. Their workup and management have evolved over the years with increasing advancements in surgical and laser therapies. This contribution focuses on describing the following benign eye and eyelid tumors and their diagnostic and treatment approaches: congenital and acquired melanocytic nevi; nevus of Ota (Hori nevus); conjunctival papilloma; seborrheic keratosis; epidermoid cyst; dermoid cyst; milium; xanthelasma; hemangioma (cherry angioma and pyogenic granuloma); neurofibroma; neurilemmoma (schwannoma); and fibroepithelial polyp. Surgical removal is the primary treatment approach for many of these benign tumors. With advancements in laser technologies, there are now several laser types that can be used in the treatment of these benign eye and eyelid tumors. Other treatment modalities include cryosurgery, electrosurgery, and topical or intralesional medications. We hope this review will provide a reference to dermatologists and ophthalmologists in their approach to evaluation and management of benign eye and eyelid tumors.